Free Trial
NASDAQ:CKPT

Checkpoint Therapeutics Q2 2024 Earnings Report

Checkpoint Therapeutics logo
$4.04 0.00 (0.00%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$4.03 -0.01 (-0.37%)
As of 04/17/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Checkpoint Therapeutics EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Checkpoint Therapeutics Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Checkpoint Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Monday, August 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Checkpoint Therapeutics' Q1 2025 earnings is scheduled for Friday, May 9, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Checkpoint Therapeutics Earnings Headlines

Checkpoint Therapeutics reports FY24 EPS ($1.42) vs ($3.17) last year
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Checkpoint Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Checkpoint Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Checkpoint Therapeutics and other key companies, straight to your email.

About Checkpoint Therapeutics

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

View Checkpoint Therapeutics Profile

More Earnings Resources from MarketBeat